Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Over the course of 12 weeks, participants taking the highest dose of amycretin (2 x 50 mg) lost an average of 13.1% of their ...

Novo Nordisk said it is now planning to advance both subcutaneous and oral formulations of amycretin into additional clinical trials. The new data follows another study that showed the ...

Novo Nordisk's shares fell on news of a clinical ... Last year, the Danish company delivered promising early-stage results for amycretin, another GLP-1 option. Amycretin is a dual agonist ...

Denmark-based pharmaceutical giant Novo Nordisk (NYSE ... the Danish company delivered promising early-stage results for amycretin, another GLP-1 option. Amycretin is a dual agonist -- it mimics ...